BioMarin

BioMarin is a biotechnology company that develops and commercializes therapeutics for the treatment of genetic diseases. Read more

Jean Jacques Bienaime's photo - Chairman & CEO of BioMarin

Chairman & CEO

Jean Jacques Bienaime

CEO Approval Rating

79/100

Founded:

1997

Status:

PublicIndependent CompanyNASDAQBMRN

BIOMARIN TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

ArmaGen has been one of BioMarin's top competitors. ArmaGen was founded in 2003, and is headquartered in Calabasas, California. ArmaGen competes in the Pharmaceuticals industry. ArmaGen generates $1.8B less revenue vs. BioMarin.

REGENXBIO is a top competitor of BioMarin. REGENXBIO is a Public company that was founded in Rockville, Maryland in 2009. REGENXBIO competes in the Biotechnology field. REGENXBIO has 2,543 fewer employees vs. BioMarin.

Sangamo is perceived as one of BioMarin's biggest rivals. Sangamo was founded in 1995, and its headquarters is in Brisbane, California. Sangamo is in the Biotechnology industry. Sangamo has 2,436 fewer employees than BioMarin.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Inventiva SA a competitor of BioMarin?

BioMarin Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$1.8B

BioMarin's revenue is the ranked 7th among it's top 10 competitors. The top 10 competitors average 6.2B. Over the last four quarters, BioMarin's revenue has grown by 13.2%. Specifically, in Q1 2021's revenue was $486M; in Q4 2020, it was $452.1M; in Q3 2020, it was $476.8M; in Q2 2020, BioMarin's revenue was $429.5M.

BioMarin Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Prosensa Therapeutics B.V.

Nov 2014

Source »
$680M
Prosensa engages in the development and commercialization of ribonucleic acid modulating therapeutics.

-

Histone Deacetylase Inhibitor, Repligen Corporation

Jan 2014

Source »
$2M
-

-

-

Jan 2013

Source »
$10M
-

-

LEAD Therapeutics

Feb 2010

Source »
$18M
-

-

-

Oct 2009

Source »
$58.5M
-

These are all the companies that BioMarin has acquired. BioMarin has acquired 7 companies and its latest acquisition was Prosensa Therapeutics B.V. in Nov 2014. Prosensa engages in the development and commercialization of ribonucleic acid modulating therapeutics.

BioMarin Funding History

Since BioMarin was founded in 1997, it has participated in 4 rounds of funding. In total BioMarin has raised $630.0M. BioMarin's last funding round was on May 2020 for a total of $550.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
May 2020
$550M
-
Debt
Jun 2018
$20M
IPO
Jul 1999
$58.5M
-
Unattributed
Feb 1997
$1.5M
-

Since BioMarin was founded in 1997, it has participated in 4 rounds of funding. In total BioMarin has raised $630.0M. BioMarin's last funding round was on May 2020 for a total of $550.0M

BioMarin Investments

No recent investments found related to BioMarin

These are all the companies that BioMarin has invested in. BioMarin has invested 7 companies and its latest investment was Prosensa Therapeutics B.V. in Nov 2014. Prosensa engages in the development and commercialization of ribonucleic acid modulating therapeutics.

BioMarin News

June 2, 2021Seeking Alpha

Too Soon To Buy

May 19, 2021Benzinga

Five-Year Data Of BioMarin's Hemophilia Gene Therapy Shows Sustained Benefit

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced an update to its previously reported results... See more »
April 28, 2021FinanzNachrichten

Allen Institute, BioMarin To Develop Gene Therapies For Rare Brain Diseases

WASHINGTON (dpa-AFX) - The Allen Institute and BioMarin Pharmaceutical Inc. (BMRN) announced a collab... See more »
March 22, 2021FiercePharma

BioMarin, Believe team up again for hemophilia awareness with patient-penned graphic novel

BioMarin, Believe team up again for hemophilia awareness with patient-penned graphic novel sharon.coe... See more »
March 21, 2021Markets Insider

BioMarin announces long-term benefit of vosoritide in Achondroplasia

BioMarin Pharmaceutical (BMRN)has announced new Phase 3 datafrom an open-label long-term extension st... See more »
March 20, 2021MarketScreener

Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN

(marketscreener.com) Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at t... See more »
March 15, 2021Seeking Alpha

One Step Back Before The Jump

March 8, 2021Benzinga

BioMarin's Hemophilia Gene Therapy Scores RMAT Designation In US

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BioMarin Pharmaceuti... See more »

BioMarin Press Releases

February 25, 2021PR Newswire

BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates

SAN RAFAEL, Calif., Feb. 25, 2021 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, ... See more »
January 26, 2021StreetInsider

BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET

SAN RAFAEL, Calif., Jan. 26, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today a... See more »
October 27, 2020GlobalNewswire

KSF REMINDS BMRN, BTU, CACC, TRQ INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

NEW ORLEANS, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former... See more »
October 18, 2020centralcharts

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - BMRN

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMari... See more »
August 4, 2020PR Newswire

BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million

SAN RAFAEL, Calif., Aug. 4, 2020 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, e... See more »
April 29, 2020PR Newswire

BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million

SAN RAFAEL, Calif., April 29, 2020 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars,... See more »
February 26, 2020PR Newswire

BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results

SAN RAFAEL, Calif., Feb. 26, 2020 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, ... See more »
January 8, 2020PR Newswire

A View from the Top on January 9, 2020 in New York

SAN RAFAEL, Calif., Jan. 8, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today an... See more »
July 9, 2019PR Newswire

BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors

SAN RAFAEL, Calif., July 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global... See more »
June 21, 2019PR Newswire

BioMarin Earns Milestone Payments from Pfizer for TALZENNA® (talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation

SAN RAFAEL, Calif., June 21, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today an... See more »

BioMarin Videos

Social Media

BioMarin Headquarters

770 Lindaro Street

San Rafael, California94901

415-506-6700

Driving Directions »

Trending Companies

BioMarin Summary

ABOUT

Overview

BioMarin is a biotechnology company that develops and commercializes therapeutics for the treatment of genetic diseases. BioMarin was founded in 1997. BioMarin's headquarters is located in San Rafael, California, USA 94901. It has raised 630.0M in 4 r...

CEO

BioMarin's Chairman & CEO, Jean Jacques Bienaime, currently has an approval rating of 79%. BioMarin's primary competitors are ArmaGen, REGENXBIO & Sangamo.

Frequently Asked Questions about BioMarin

  1. When was BioMarin founded?

    BioMarin was founded in 1997
  2. Who is BioMarin's CEO?

    BioMarin's CEO is Jean Jacques Bienaime
  3. How much revenue does BioMarin generate?

    BioMarin generates $1.8B in revenue
  4. How much funding does BioMarin have?

    BioMarin has historically raised $630M in funding
  1. Where is BioMarin's headquarters?

    BioMarin's headquarters is in San Rafael California, USA
  2. How many employees does BioMarin have?

    BioMarin has 2,849 employees
  3. Who are BioMarin's competitors?

    BioMarin's top competitors are ArmaGen, REGENXBIO, Sangamo